{
    "ticker": "SAVA",
    "name": "Cassava Sciences, Inc.",
    "description": "Cassava Sciences, Inc. is a clinical-stage biotechnology company dedicated to the development of innovative therapies for neurodegenerative diseases, with a primary focus on Alzheimer's disease. Founded in 2002 and headquartered in Austin, Texas, Cassava is at the forefront of scientific advancements aimed at addressing the unmet needs of patients suffering from cognitive decline and dementia. The company is developing a new class of oral drugs that target the underlying biology of Alzheimer's, with the goal of improving cognition and quality of life for patients. Cassava's lead product candidate, PTI-125, is in clinical trials and has shown promising results in early studies. The company is also engaged in research to better understand the mechanisms of neurodegenerative diseases and seeks to transform the treatment paradigm for these conditions. With a commitment to scientific integrity and patient welfare, Cassava Sciences continues to advance its clinical programs while fostering collaborations to expedite the development of its therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Austin, Texas, USA",
    "founded": "2002",
    "website": "https://www.cassavasciences.com",
    "ceo": "Remi Barbier",
    "social_media": {
        "twitter": "https://twitter.com/CassavaSciences",
        "linkedin": "https://www.linkedin.com/company/cassava-sciences-inc/"
    },
    "investor_relations": "https://ir.cassavasciences.com",
    "key_executives": [
        {
            "name": "Remi Barbier",
            "position": "CEO"
        },
        {
            "name": "Diana C. E. T. B. K. K. T. H. E. R. K. Y.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Candidates",
            "products": [
                "PTI-125"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cassava Sciences, Inc. | Innovative Therapies for Alzheimer's Disease",
        "meta_description": "Explore Cassava Sciences, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, especially Alzheimer's disease.",
        "keywords": [
            "Cassava Sciences",
            "Alzheimer's Disease",
            "Neurodegenerative Diseases",
            "Biotechnology",
            "PTI-125"
        ]
    },
    "faq": [
        {
            "question": "What is Cassava Sciences known for?",
            "answer": "Cassava Sciences is known for developing innovative therapies for Alzheimer's disease and other neurodegenerative conditions."
        },
        {
            "question": "Who is the CEO of Cassava Sciences?",
            "answer": "Remi Barbier is the CEO of Cassava Sciences, Inc."
        },
        {
            "question": "Where is Cassava Sciences headquartered?",
            "answer": "Cassava Sciences is headquartered in Austin, Texas, USA."
        },
        {
            "question": "What is Cassava's lead product candidate?",
            "answer": "Cassava's lead product candidate is PTI-125, which is being developed for the treatment of Alzheimer's disease."
        },
        {
            "question": "When was Cassava Sciences founded?",
            "answer": "Cassava Sciences was founded in 2002."
        }
    ],
    "competitors": [
        "BIIB",
        "ADUS",
        "SNY",
        "PTCT"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "VRTX"
    ]
}